After Golden Cross, Greenwich LifeSciences, Inc. (GLSI)'s Technical Outlook is BrightZacks Investment Research • 12/21/22
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023Business Wire • 12/01/22
Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical TrialBusiness Wire • 08/11/22
Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical TrialBusiness Wire • 08/03/22
Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to ProceedBusiness Wire • 07/12/22
Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO MeetingBusiness Wire • 05/23/22
Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast PotentialSeeking Alpha • 04/21/22
Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International ConferencesBusiness Wire • 04/20/22
Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast CancerBusiness Wire • 04/19/22
Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR MeetingBusiness Wire • 03/03/22